The France’s Public Health Authority (HAS) has advised the government against using the Valneva (VLS.PA) vaccine against Covid-19 as part of its broader vaccination strategy.
HAS has only recommended Sanofi’s (SASY.PA, GSK’s (GSK.L), VidPrevtyn Beta, and Novavax (NVAX.O) Nuvaxovid vaccines for vaccination of people who cannot receive mRNA vaccines.
“However, HAS does not recommend that the use of Valneva’s VLA2001 vaccine be included in the current primary vaccination strategy,” he added.
According to Elizabeth Buffet, at a press conference, “There is no clinical efficacy or immunological data on the current variants. Therefore, they are not notified at this time.”
French drugmaker Valneva, whose shares have been volatile in recent months, won EU regulatory approval in June for a Covid-19 vaccine, but was recently forced to cut funding and jobs due to low levels of orders.
Read also: Marketing of a vaccine authorized by the French pharmaceutical company Valneva
Always be the first to know.
Consumer’s Choice Award for the sixth year in a row and Five Stars Online.
Download our free app.
Emily Brontë is a journalist and feature writer specialising in culture, entertainment, literature, and current affairs. She is dedicated to producing clear, accurate reporting that helps readers stay informed about developments in the UK and around the world.
